West Pharmaceutical Services (WST) Interest Expenses (2009 - 2026)

West Pharmaceutical Services (WST) has reported Interest Expenses for 18 consecutive years, with $134.9 million the latest figure, recorded in Q2 2026.

• Quarterly Interest Expenses rose 134800.0% year-over-year to $134.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $134.9 million (up 799.33% YoY) and the FY2025 annual result came in at $146.4 million, up 350.46% from the prior year.
• Interest Expenses declined to $134.9 million in Q2 2026 per WST's latest filing, from $140.3 million in the prior quarter.
• Over the last five years, Interest Expenses for WST reached as high as $140.3 million in Q1 2026 and fell as low as -$800000.0 in Q4 2024.
• A 5-year average of $32.4 million and a median of $5.1 million in 2023 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2024 — Interest Expenses plunged 105.37% — and 2026, when it jumped 134800.0%.
• Year by year, Interest Expenses stood at $7.1 million in 2022, then soared by 109.86% to $14.9 million in 2023, then tumbled by 105.37% to -$800000.0 in 2024, then jumped by 3025.0% to $23.4 million in 2025, then jumped by 476.5% to $134.9 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $134.9 million, $140.3 million, and $23.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.